327 related articles for article (PubMed ID: 11068448)
1. [The new Parkinson's disease drugs].
Hasegawa K
Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
3. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
4. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
5. [Wearing-off phenomenon--neurological approach].
Ishikawa A
Nihon Rinsho; 2000 Oct; 58(10):2100-3. PubMed ID: 11068454
[TBL] [Abstract][Full Text] [Related]
6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
7. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
9. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
10. How should we treat a patient with early Parkinson's disease?
Tsouli S; Konitsiotis S
Int J Clin Pract; 2010 Aug; 64(9):1210-9. PubMed ID: 20653797
[TBL] [Abstract][Full Text] [Related]
11. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
12. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
13. Mid-stage parkinsonism with mild motor fluctuations.
Tolosa E; Valldeoriola F
Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
[TBL] [Abstract][Full Text] [Related]
14. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
15. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
16. Other pharmacological treatments for motor complications and dyskinesias.
Waters C
Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease therapy: treatment of early and late disease.
Jankovic J
Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
[TBL] [Abstract][Full Text] [Related]
18. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
19. Drug selection and timing of initiation of treatment in early Parkinson's disease.
Schapira AH; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
[TBL] [Abstract][Full Text] [Related]
20. Advances in the delivery of treatments for Parkinson's disease.
Johnston TH; Fox SH; Brotchie JM
Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
